Tag Archives: Nonalcoholic Steatohepatitis Therapeutics Market

Nonalcoholic Steatohepatitis Therapeutics Market Outlook and Forecast up to 2025

The global nonalcoholic steatohepatitis therapeutics market is dominated by companies such as Intercept Pharmaceuticals Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Zydus Cadila, AstraZeneca plc., Gilead Sciences, Inc., and Immuron Ltd. Key companies are focusing on the introduction of new drugs and therapeutics to treat nonalcoholic steatohepatitis (NASH). As per the Natural Medical Journal, the occurrence of nonalcoholic fatty liver diseases is expected to increase in the U.S., which is likely to propel the global market in the years to come. This is anticipated to benefit the global nonalcoholic steatohepatitis therapeutics market in many ways. Transparency Market Research (TMR), in its new report, states that key companies are targeting to enhance the healthcare infrastructure and invest more on research and development activities to discover a new drug to treat nonalcoholic fatty liver diseases.

This 65 page report gives readers a comprehensive overview of the nonalcoholic steatohepatitis therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

The prevalence of NASH in people with severe obesity is expected to be the highest,” states a TMR analyst. The global nonalcoholic steatohepatitis therapeutics market is expected to reach US$20.27 bn by 2025. Based on drug type, the global nonalcoholic steatohepatitis therapeutics market is expected to be led by elafibranor segment. The elafibranor segment is predicted to reach US$10,121.94 mn by 2025. The many benefits of elafibranor to treat NASH have made this drug type popular than others. Key companies are taking efforts to invest more into research and development activities to enhance this drug class, which is expected to propel this segment. This pipeline drug type is expected to have better prospects in the future as there are not many treatments available to treat NASH, says a TMR analysts. The rising occurrence of NASH is expected to benefit this drug type in the near future.

Key companies operating in the global nonalcoholic steatohepatitis therapeutics market are likely to increase their research and development activities to introduce new technologies to manufacture new drugs to treat NASH. The introduction of new innovative effective, and safe drugs is expected to propel the global nonalcoholic steatohepatitis therapeutics market. Manufacturers are focusing on changing government rules and drug approval procedures before introducing new drugs in the global market. Stringent government rules are expected to restrict the introduction of new drugs, which is a key challenge for the manufacturers.

Rising obesity to strengthen global market

Nonalcoholic steatohepatitis commonly affects people with diabetes or obese people. The rising number of people with diabetes is expected to drive the demand for NASH therapeutics. The increasing pool of obese people is another factor expected to contribute towards the growth of the global nonalcoholic steatohepatitis therapeutics market. The developments in the healthcare infrastructure and therapeutic strategies are predicted to benefit the global nonalcoholic steatohepatitis therapeutics market.

Weak pipeline continues to hamper global market

A weak product pipeline is expected to hamper the growth of the global nonalcoholic steatohepatitis therapeutics market. There are not many therapies and drugs to treat NASH, which is a challenge for the leading players operating in this global market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving nonalcoholic steatohepatitis therapeutics market during 2015 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Developing nations to offer new opportunities

Key companies are likely to target the developing nations to capture a significant share of the untapped market. Many emerging nations are offering growth opportunities to the leading manufacturers of nonalcoholic steatohepatitis therapeutics. The entry of new companies is also predicted to benefit the global market for nonalcoholic steatohepatitis therapeutics. However, with the entry of new companies, the global market is expected to be highly competitive in nature.

This information is based on the findings of a report published by Transparency Market Research titled “Nonalcoholic Steatohepatitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015-2025.”

The nonalcoholic steatohepatitis therapeutics market is segmented as follows:

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type

  • Overview
  • Potential Drug Candidates in Phase III
  • Obeticholic Acid (OCA)
  • Aramchol (arachidyl amido cholanoic acid)
  • Saroglitazar
  • Elafibranor

 

Nonalcoholic Steatohepatitis Therapeutics Market – An Emerging Worldwide Industry

Nonalcoholic fatty liver disease (NAFLD) is a disorder categorized by excess fat in the liver of people who drink little to no alcohol. No direct cause has yet been identified, however obesity and insulin resistance are believed to have major roles. Most often, NAFLD goes relatively undetected, as a liver can remain fatty without obstructing its function. Though, NAFLD can progress into a far more severe condition known as nonalcoholic steatohepatitis (NASH), a disease characterized by inflammation and irreversible cell death. NASH is a disease that advances over time. Over a period of ten years up to 20% of patients with NASH develop cirrhosis of the liver, and 10% die from the disease. At present, NASH is one of the leading causes of liver transplants in the U.S., with a considerable proportion of the general population currently suffering from the disease. NAFLD and NASH are both closely related to diabetes and obesity, and together are now considered as the leading cause of liver disease in Western countries. Thus, there is an urgent need for effective treatment options for these diseases. The need for treatment is expected to propel the growth of NASH therapeutics in coming years.

This 65 page report gives readers a comprehensive overview of the nonalcoholic steatohepatitis therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report provides a list of the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market followed by Obeticholic Acid (OCA) market and the market for Elafibranor is expected to grow at the highest CAGR.

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes epidemiology of Nonalcoholic steatohepatitis (NASH) by region, to provide a thorough analysis of the overall addressable global market for the NASH therapeutics. Moreover, the report provides qualitative information about diagnosis and treatment of NASH.

The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the NASH market across different regions worldwide. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving nonalcoholic steatohepatitis therapeutics market during 2015 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).

 

Nonalcoholic Steatohepatitis Therapeutics Market – Current status and future trends

Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot

Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.

Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely to have nonalcoholic steatohepatitis (NASH). Most patients are asymptomatic and biopsy is essential to confirm the diagnosis. Treatment mainly entails elimination of causes and risk factors.

This 65 page report gives readers a comprehensive overview of the nonalcoholic steatohepatitis therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

Driving the growth in the global market for nonalcoholic steatohepatitis therapeutics is the rising instances of obesity and diabetes. Another factor boosting the market is the thrust on research and development. In fact, a noticeable trend in the market has been the focus on developing novel therapeutics for the curing NASH by big biopharmaceutical manufacturing companies. Propelled by such factors, the global market for nonalcoholic steatohepatitis therapeutics is slated to expand at a robust 10.7% CAGR between 2015 and 2025 to attain a value of US$20.27 bn by 2025.

Elafibranor Drug Holds a Sway over Market by Dint of being Most Advanced

The cause for nonalcoholic steatohepatitis (NASH) is unclear and research is being carried out to find effective treatments. At present, treatment of NASH focuses on controlling some of the medical conditions associated with it such as diabetes and obesity and monitoring for advancement. As with nonalcoholic fatty liver disease, people with NASH should be vaccinated against hepatitis A and B if they are not immune already.

Depending upon the type of drug, the global market for nonalcoholic steatohepatitis (NASH) can be segregated into potential phase III candidates such as Saroglitazar, Obeticholic acid (OCA), Aramchol, and Elafibranor. There are others too in the Phase I and Phase II clinical trials. Among the different types of drugs Elafibranor is predicted to hold maximum share in the market and also exhibit maximum growth rate. This is because Elafibranor is the most advanced drug in this category. It is followed by Obeticholic Acid (OCA) in the market.

Currently, Intercept Pharmaceuticals, in collaboration with DSP, is developing obeticholic acid for commercialization in the United States and European countries. This drug is anticipated to receive commercial approval by the end 2017.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving nonalcoholic steatohepatitis therapeutics market during 2015 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Developing Nations Power Growth in Asia Pacific Market

While the prevalence of nonalcoholic steatohepatitis (NASH) is growing across the globe, it is the developed regions of Europe and North America that are seeing maximum instances on account of increasing occurrence of lifestyle related conditions such as obesity and diabetes. In North America particularly, the rate of obesity has almost doubled in children. Obesity also leads to diabetes and high blood cholesterol, which can aggravate health issues of those suffering from NASH.

In Europe, nonalcoholic steatohepatitis (NASH) is most prevalent in the countries of Spain, Germany, Italy, France and, the U.K. Developing economies, especially in Asia-Pacific are considered high growth markets for nonalcoholic steatohepatitis (NASH) therapeutics and are forecasted to grow at double digits in the foreseeable future. This is because of the alarming increase in nonalcoholic fatty liver diseases in countries of Korea, China, and Japan.

Some of the prominent names operating in the global market for nonalcoholic steatohepatitis (NASH) are Astazeneca Plc., Intercept Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, Gilead Sciences, Inc., Zydus Cadila, Immuron Ltd., Conatus Pharmaceuticals, and Tobira Therapeutics, Inc.

Nonalcoholic Steatohepatitis Therapeutics Market – Current status and future trends

Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot

Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.

Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely to have nonalcoholic steatohepatitis (NASH). Most patients are asymptomatic and biopsy is essential to confirm the diagnosis. Treatment mainly entails elimination of causes and risk factors.

This 65 page report gives readers a comprehensive overview of the nonalcoholic steatohepatitis therapeutics market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

Driving the growth in the global market for nonalcoholic steatohepatitis therapeutics is the rising instances of obesity and diabetes. Another factor boosting the market is the thrust on research and development. In fact, a noticeable trend in the market has been the focus on developing novel therapeutics for the curing NASH by big biopharmaceutical manufacturing companies. Propelled by such factors, the global market for nonalcoholic steatohepatitis therapeutics is slated to expand at a robust 10.7% CAGR between 2015 and 2025 to attain a value of US$20.27 bn by 2025.

Elafibranor Drug Holds a Sway over Market by Dint of being Most Advanced

The cause for nonalcoholic steatohepatitis (NASH) is unclear and research is being carried out to find effective treatments. At present, treatment of NASH focuses on controlling some of the medical conditions associated with it such as diabetes and obesity and monitoring for advancement. As with nonalcoholic fatty liver disease, people with NASH should be vaccinated against hepatitis A and B if they are not immune already.

Depending upon the type of drug, the global market for nonalcoholic steatohepatitis (NASH) can be segregated into potential phase III candidates such as Saroglitazar, Obeticholic acid (OCA), Aramchol, and Elafibranor. There are others too in the Phase I and Phase II clinical trials. Among the different types of drugs Elafibranor is predicted to hold maximum share in the market and also exhibit maximum growth rate. This is because Elafibranor is the most advanced drug in this category. It is followed by Obeticholic Acid (OCA) in the market.

Currently, Intercept Pharmaceuticals, in collaboration with DSP, is developing obeticholic acid for commercialization in the United States and European countries. This drug is anticipated to receive commercial approval by the end 2017.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving nonalcoholic steatohepatitis therapeutics market during 2015 – 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Developing Nations Power Growth in Asia Pacific Market

While the prevalence of nonalcoholic steatohepatitis (NASH) is growing across the globe, it is the developed regions of Europe and North America that are seeing maximum instances on account of increasing occurrence of lifestyle related conditions such as obesity and diabetes. In North America particularly, the rate of obesity has almost doubled in children. Obesity also leads to diabetes and high blood cholesterol, which can aggravate health issues of those suffering from NASH.

In Europe, nonalcoholic steatohepatitis (NASH) is most prevalent in the countries of Spain, Germany, Italy, France and, the U.K. Developing economies, especially in Asia-Pacific are considered high growth markets for nonalcoholic steatohepatitis (NASH) therapeutics and are forecasted to grow at double digits in the foreseeable future. This is because of the alarming increase in nonalcoholic fatty liver diseases in countries of Korea, China, and Japan.

Some of the prominent names operating in the global market for nonalcoholic steatohepatitis (NASH) are Astazeneca Plc., Intercept Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., GENFIT SA, Gilead Sciences, Inc., Zydus Cadila, Immuron Ltd., Conatus Pharmaceuticals, and Tobira Therapeutics, Inc.

 

Nonalcoholic Steatohepatitis Therapeutics Market Witnesses Rising Demand and Investment from R&D Activities

According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2025”, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.

Nonalcoholic Steatohepatitis (NASH) is a syndrome that advances in patients who are not alcoholic; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware of their liver problem. However, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and no longer able to work properly. It develops most frequently in patients with at least one of the following risk factors as obesity, dyslipidemia, and glucose intolerance. Pathogenesis is not clearly understood but seems to be linked to insulin resistance. Most of the patients are asymptomatic. Laboratory outcomes include elevations in aminotransferase levels. Biopsy is essential to confirm the diagnosis. Treatment mainly focusses on elimination of causes and risk factors.

Read Full Report: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

The prevalence of NASH and NAFLD is increasing across the globe but it is more in developed regions such as North America. Both NASH and NAFLD are becoming more common, perhaps because of the greater number of Americans with obesity. In the past few years, the rate of obesity has almost doubled in adults and tripled in children. Obesity also adds to diabetes and high blood cholesterol, which can further complicate the health of people suffering from NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.

Currently, no specific therapies exist for NASH treatment. The most important recommendations given to persons with this disease are weight reduction (if overweight), following a balanced and healthy diet, increasing physical activity, avoiding alcohol and avoiding unnecessary medications.

The NASH market is segmented based on drug type which includes potential phase III candidates such as Obeticholic acid (OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the report enlists the candidates in Phase I and Phase II clinical trials. Based on the drug type, Elafibranor is expected to account for a major share of this market and the market for Elafibranor is expected to grow at the highest CAGR. This growth is majorly due to Elafibranor which is considered to be the most advanced drug in this category.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Major players in this market are Astazeneca Plc (U.K.), Intercept Pharmaceuticals Inc. (U.S.), Galmed Pharmaceuticals Ltd. (Israel), GENFIT SA (France), Gilead Sciences, Inc. (U.S.), Zydus Cadila (India), Immuron Ltd. (Australia), Conatus Pharmaceuticals (U.S.), and Tobira Therapeutics, Inc. (U.S.).

The Nonalcoholic Steatohepatitis (NASH) Therapeutics market has been segmented as follows:

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type

  • Overview
  • Potential Drug Candidates in Phase III
    • Obeticholic Acid (OCA)
    • Aramchol (arachidyl amido cholanoic acid)
    • Saroglitazar
    • Elafibranor